BAXTER INTERNATIONAL INC (BAX) Stock News
NYSE:BAX - New York Stock Exchange, Inc. - US0718131099 - Common Stock - Currency: USD
BAX Latest News, Press Relases and Analysis
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Unpacking Q1 Earnings: Baxter (NYSE:BAX) In The Context Of Other Medical Devices & Supplies - Diversified Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.
BAX Q1 Earnings Call: Revenue Tops Expectations, Margins Face Tariff and Cost Pressures
Healthcare company Baxter International (NYSE:BAX) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 5.4% year on year to $2.63 billion. The company expects next quarter’s revenue to be around $2.82 billion, close to analysts’ estimates. Its non-GAAP profit of $0.55 per share was 14.8% above analysts’ consensus estimates.
Baxter Declares Quarterly Dividend
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter Reports First-Quarter 2025 Results
Conagra to sell Chef Boyardee to private equity firm for $600M
The sale comes as the CPG giant focuses on its core snacks and frozen meals offerings, including Slim Jim and Healthy Choice.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Baxter to Present at Bank of America Securities 2025 Health Care Conference
Will BAX's Q1 Earnings Improve Following Transformation Completion?
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
AngloGold Ashanti (AU): Among the 10 Best Metal Stocks to Buy According to Billionaires
We recently published a list of 10 Best Metal Stocks to Buy According to Billionaires. In this article, we will look at where AngloGold Ashanti plc (NYSE:AU) stands against other best metal stocks to buy. When investing in the best metal stocks, the stakes are high, and the potential rewards are even higher. Metals power the […]
Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Royalty Pharma Plc (NASDAQ:RPRX) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade […]
Curtiss-Wright Corporation (CW): Among Stocks Insiders Were Buying In Q1 2025
We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where Curtiss-Wright Corporation (NYSE:CW) stands against other stocks insiders were buying in Q1 2025. About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while […]
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Baxter (BAX): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Baxter’s stock price fell to $36.42. Shareholders have lost 7.3% of their capital, which is disappointing considering the S&P 500 has climbed by 1.5%. This might have investors contemplating their next move.